(Q42168264)

17 October 2017

title

Antitumor effects of 5-fluorouracil on human colon cancer cell lines: antagonism by levamisole (English)

1 reference

17 October 2017

1 reference

1 reference

Eric A Wiebke

1

1 reference

17 October 2017

Neil A Grieshop

2

1 reference

17 October 2017

Patrick J Loehrer

3

1 reference

17 October 2017

George J Eckert

4

1 reference

17 October 2017

Richard A Sidner

5

1 reference

17 October 2017

publication date

1 May 2003

1 reference

Journal of Surgical Research

17 October 2017

published in

1 reference

17 October 2017

volume

111

1 reference

17 October 2017

issue

1

1 reference

17 October 2017

page(s)

63-69

1 reference

Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer

17 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Levamisole plus 5-fluorouracil inhibits the growth of human colorectal xenografts in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma: a Veterans Administration Lung Cancer Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Levamisole in the treatment of advanced breast cancer. A ten-year follow-up of a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Levamisole in the treatment of stage II breast cancer. Five-year follow-up of a randomized double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. II. 5-year results and influence of levamisole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Levamisole in advanced human breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Long-term survival following levamisole or placebo adjuvant treatment of colorectal cancer: a Western Cancer Study Group Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Late mortality and levamisole adjuvant therapy in colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Levamisole Potentiation of Fluorouracil Antiproliferative Activity Mimicked by Orthovanadate, an Inhibitor of Tyrosine Phosphatase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Effect of levamisole on major histocompatibility complex class I expression in colorectal and breast carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

A rapid single step staining technique for DNA analysis by flow microfluorimetry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Re: Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Enhancement of in vitro lipopolysaccharide-stimulated interleukin-1 production by levamisole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Concentrations of levamisole required for enhanced proliferation of human lymphocytes and phagocytosis by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Potentiation of interleukin-2 activity by levamisole and imidazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

In vitro stimulation of spleen cell cultures by poly I: Poly C and levamisole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Cellular immune modulation after a single high dose of Levamisole in patients with carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Levamisole inactive in treatment of four animal tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-4804%2803%2900053-2

10.1016/S0022-4804(03)00053-2

7 January 2021

Identifiers

DOI

1 reference

17 October 2017

1 reference